CD4


Journal

Tuberculosis (Edinburgh, Scotland)
ISSN: 1873-281X
Titre abrégé: Tuberculosis (Edinb)
Pays: Scotland
ID NLM: 100971555

Informations de publication

Date de publication:
07 2020
Historique:
received: 22 08 2019
revised: 13 04 2020
accepted: 13 04 2020
entrez: 4 8 2020
pubmed: 4 8 2020
medline: 4 9 2021
Statut: ppublish

Résumé

Interferon-γ release assays cannot differentiate latent from active tuberculosis (TB), nor identify the recently infected with increased risk of active disease. The objective of this study was to identify biomarkers of recent infection following exposure to tuberculosis, to increase the positive predictive value for incipient TB. Contacts to patients with pulmonary TB were tested repeatedly with interferon-γ release assays and flow-cytometry. Proliferative CD4

Identifiants

pubmed: 32741535
pii: S1472-9792(20)30126-8
doi: 10.1016/j.tube.2020.101959
pii:
doi:

Substances chimiques

Antigens, Bacterial 0
Bacterial Proteins 0
CFP-10 protein, Mycobacterium tuberculosis 0
ESAT-6 protein, Mycobacterium tuberculosis 0
IFNG protein, human 0
Tuberculin 0
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101959

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Emilie Wahren Borgström (EW)

Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. Electronic address: emilie.wahren-borgstrom@sll.se.

Gabrielle Fröberg (G)

Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. Electronic address: gabrielle.froberg@sll.se.

Margarida Correia-Neves (M)

Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B's, PT Government Associate Laboratory, Braga/Guimarães, Portugal. Electronic address: mcorreianeves@med.uminho.pt.

Fredrik Bosdotter Atterfelt (FB)

Public Health Agency of Sweden, Nobel's väg 18, Solna, Stockholm, Sweden. Electronic address: fredrik.bosdotter.atterfelt@gu.se.

Jan Bellbrant (J)

Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. Electronic address: jan.bellbrant@sll.se.

Robert Szulkin (R)

Division of Family Medicine, Department of Neurobiology, Care Science and Society, Karolinska Institutet, Huddinge, Sweden; Scandinavian Development Services, Danderyd, Sweden. Electronic address: Robert.Szulkin@scanddev.se.

Erja Chryssanthou (E)

Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden. Electronic address: erja.chryssanthou@sll.se.

Kristian Ängeby (K)

Department of Clinical Science and Education, Emergency Medicine, Stockholm South General Hospital, Karolinska Institute, Stockholm, Sweden. Electronic address: kristian.angeby@ki.se.

Teghesti Tecleab (T)

Public Health Agency of Sweden, Nobel's väg 18, Solna, Stockholm, Sweden. Electronic address: teghesti.tecleab@fohm.se.

Morten Ruhwald (M)

Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark. Electronic address: moru@ssi.dk.

Peter Andersen (P)

Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark. Electronic address: pa@ssi.dk.

Gunilla Källenius (G)

Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Electronic address: gunilla.kallenius@ki.se.

Judith Bruchfeld (J)

Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. Electronic address: Judith.Bruchfeld@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH